华东医药：2026年第一季度报告(英文版)

华东医药：2026年第一季度报告(英文版)

查股网  2026-07-09  华东医药(000963)公司公告

Stockcode:000963Stockabbreviation:HuadongMedicineAnnouncementNo.:2026-030

HuadongMedicineCo.,Ltd.FirstQuarterlyReport2026

TheCompanyandallmembersoftheBoardofDirectorsherebyguaranteethattheinformationpresentedinthisreportisauthentic,accurateandcompleteandfreeofanyfalserecords,misleadingstatementsormaterialomissions.ImportantDeclaration:

1.TheBoardofDirectors,directorsandseniormanagementofHuadongMedicineCo.,Ltd.(hereinafterreferredtoasthe"Company")herebyguaranteethattheinformationpresentedintheReportisauthentic,accurateandcompleteandfreeoffalserecords,misleadingstatementsormaterialomissions,andshallundertakeindividualandjointlegalliabilities.

2.TheCompany'slegalrepresentative,theofficerinchargeofaccounting,andtheheadofAccountingDepartment(accountingmanager)herebydeclarethatthefinancialinformationinthisquarterlyreportisauthentic,accurateandcomplete.

3.HastheFirstQuarterlyReportbeenaudited?

□Yes?NoAccordingto“StockListingRulesoftheShenzhenStockExchange”,iflistedcompanieshavebothChineseandotherlanguageversionofpublicnotice,theyshouldensurethecontentofbothversionsarethesame.Inthecaseofdiscrepancy,theoriginalversioninChineseshallprevail.

I.KeyFinancialData

(I)Keyaccountingdataandfinancialindicators

WhethertheCompanyneedstoperformaretroactiveadjustmentorrestatementofpreviousaccountingdata

□Yes?No

CurrentreportingperiodSameperiodlastyearYear-on-yearchangeforthereportingperiod(%)
Operatingrevenue(RMB)11,183,450,824.2710,735,787,899.824.17%
Netprofitsattributabletoshareholdersofthelistedcompany(RMB)1,002,189,357.16914,708,484.709.56%
Netprofitsattributabletoshareholdersofthelistedcompanyafterdeductionofnon-recurringprofitandloss(RMB)989,719,668.99897,337,982.4210.30%
Netcashflowfromoperatingactivities(RMB)-852,335,762.63-832,728,693.88-2.35%
Basicearningspershare(RMB/share)0.57150.52249.40%
Dilutedearningspershare(RMB/share)0.57150.52139.63%
Weightedaveragereturnonequity3.97%3.88%0.09%
EndofthecurrentreportingperiodEndofthelastyearChangefromprioryear-end(%)
Totalassets(RMB)39,908,042,564.9439,038,036,320.922.23%
Owners'equityattributabletoshareholdersoflistedcompanies(RMB)25,733,074,032.1024,811,339,992.993.71%

TheCompany'stotalsharecapitalasofthetradingdaypriortodisclosure:

TheCompany’stotalsharecapitalasofthetradingdaypriortodisclosure(shares)1,753,736,848.00

Fullydilutedearningspersharebasedonthelatestsharecapital:

Preferreddividendspaid(RMB)0.00
Paidperpetualbondinterest(RMB)0.00
Fullydilutedearningspersharebasedonthelatestsharecapital(RMB/share)0.5715

(II)Non-recurringprofitandlossitemsandamounts

?Applicable□Notapplicable

Unit:RMB

ItemAmountduringthecurrentreportingperiodDescription
Profits/lossesondisposalofnon-currentassets(includingthewritten-offpartoftheaccruedimpairmentprovisionofassets)534,949.84
Governmentgrantsincludedinthe22,334,120.97
currentprofitsandlosses(exceptthosethatarecloselyrelatedtothenormalbusinessoperationoftheCompany,complywithnationalpoliciesandregulations,areenjoyedinaccordancewiththedefinedcriteria,andhavealastingimpactontheCompany'sprofitsandlosses)
Othernon-operatingrevenueandexpensesotherthanthosementionedabove-7,779,473.38
Less:Amountaffectedbyincometax1,182,827.86
Amountaffectedbyminorityinterests(aftertax)1,437,081.40
Total12,469,688.17--

Detailsofotherprofitandlossitemsconformingtothedefinitionofnon-recurringprofitsandlosses

□Applicable?NotapplicableTherearenootherprofitandlossitemsthatmeetthedefinitionofnon-recurringprofitsandlosses.Explanationforrecognizinganitemlistedasanon-recurringprofitandlossintheInterpretativeAnnouncementNo.1onInformationDisclosureCriteriaforPublicListedCompanies-Non-RecurringProfitsandLossesasanitemofrecurringprofitandloss

□Applicable?NotapplicableTheCompanydidnotrecognizeanyitemofnon-recurringprofitandlossitemslistedintheInterpretativeAnnouncementNo.1onInformationDisclosureCriteriaforPublicListedCompanies-Non-RecurringProfitsandLossesasanitemofrecurringprofitandloss.

(III)Detailsandreasonsforchangesinkeyaccountingdataandfinancialindicators

?Applicable□Notapplicable

Unit:RMB10,000

ItemsinthebalancesheetClosingbalanceOpeningbalancePercentagechangeReasonsforchanges
Notesreceivable-621.34-100.00%Mainlyattributabletothedecreaseincommercialacceptancebillsreceivableduringthecurrentperiod
Othercurrentassets13,927.4922,234.33-37.36%MainlyattributabletothedecreaseincreditableVATinputtaxattheendoftheperiod
Othercurrentliabilities3,494.291,044.36234.59%MainlyattributabletotheincreaseinVAToutputtaxpendingcarryoverduringthecurrentperiod
Employeecompensationpayable23,713.8541,159.88-42.39%Mainlyattributabletoremunerationpaidduringthecurrentperiod
Othercomprehensiveincome-7,483.69577.07-1396.85%Mainlyattributabletochangesinforeigncurrencytranslationdifferencesduringthecurrentperiod
ItemsintheincomestatementAmountinthecurrentperiodAmountinthepreviousperiodPercentagechangeReasonsforchanges
R&Dexpenses35,036.5351,537.69-32.02%Keyprogramswereprogressedsmoothlyinclinicalstudies
duringtheperiod.ExpendituresrelatedtoPhaseIIIclinicalprogramsmetthecapitalizationcriteriaandwerecapitalizedduringthecurrentperiod,resultinginacorrespondingdecreaseinR&Dexpenses
Financialexpenses-472.531,461.80-132.33%Mainlyattributabletotheincreaseinexchangeearninginthecurrentperiod
Investmentincome-2,231.03-4,262.4147.66%Mainlyattributabletotheincreaseininvestmentincomerecognizedfromassociatesinthecurrentperiod
Otherincome3,123.037,364.16-57.59%Mainlyattributabletothedecreaseingovernmentgrantsduringthecurrentperiod
Proceedsfromdisposalofassets53.49-1,454.10103.68%Mainlyattributabletothedecreaseinnetlossesfromassetdisposalduringthecurrentperiod
Non-operatingexpenses909.542,807.54-67.60%Mainlyattributabletothedecreaseinexternaldonationsmadeduringthecurrentperiod
ItemsinthecashflowstatementAmountinthecurrentperiodAmountinthepreviousperiodPercentagechangeReasonsforchanges
Netcashflowsfrominvestingactivities-39,140.04-64,583.9439.40%Mainlyattributabletothedecreaseininvestmentinthecurrentperiod
Netcashflowfromfinancingactivities3,521.20-8,683.86140.55%Mainlyattributabletotheyear-on-yeardecreaseintherepaymentofinterest-bearingliabilities

II.ShareholderInformation

(I)Totalnumberofcommonshareholders,numberofpreferredshareholderswithrestoredvotingrightsandshareholdingsoftop10shareholders

Unit:Shares

Totalnumberofcommonshareholdersattheendofthereportingperiod84,304Totalnumberofpreferredshareholderswithrestoredvotingrightsattheendofthereportingperiod(ifany)0
Particularsaboutthetop10shareholders(excludingshareslentthroughrefinancing)
NameofshareholderNatureofshareholderShareholdingratio(%)NumberofsharesheldNumberofsharesheldwithtradingrestrictionsPledged,markedorlocked-upstatus
StatusofsharesQuantity
ChinaGrandEnterprises,Inc.Domesticnon-state-ownedcorporation41.68%730,938,1570Pledged138,640,000
HangzhouHuadongMedicineGroupCo.,Ltd.State-ownedcorporation16.42%288,000,0000Notapplicable0
HongKongSecuritiesOverseascorporation2.22%38,923,3300Notapplicable0
ClearingCompanyLimited
NewChinaLifeInsuranceCo.,Ltd.-Dividend-IndividualDividend-018L-FH002ShenzhenOthers2.05%35,903,8420Notapplicable0
NewChinaLifeInsuranceCo.,Ltd.-Traditional-GeneralInsuranceProducts-018L-CT001ShenzhenOthers1.32%23,204,0140Notapplicable0
IndustrialandCommercialBankofChinaLimited-ZhongOuAMCMedicalandHealthHybridSecuritiesInvestmentFundOthers1.21%21,182,3290Notapplicable0
ChinaSecuritiesFinanceCorporationLimitedDomesticnon-state-ownedcorporation1.09%19,095,3440Notapplicable0
NationalSocialSecurityFund-Portfolio112Others1.00%17,589,7440Notapplicable0
BankofShanghaiCo.,Ltd.-YinhuaCSIInnovativePharmaceuticalIndustryTradedOpen-endedIndexSecuritiesInvestmentFundOthers0.74%13,013,8980Notapplicable0
ChinaConstructionBankCorporation-EFundCSI300MedicalandHealthTradingOpenIndexOthers0.70%12,343,8700Notapplicable0
SecuritiesInvestmentFund
Informationaboutthetop10shareholderswithouttradingrestrictions(excludingshareslentthroughconversionsandlocked-upsharesforseniormanagement)
NameofshareholderNumberofsharesheldwithouttradingrestrictionsTypeofshares
TypeofsharesQuantity
ChinaGrandEnterprises,Inc.730,938,157RMBcommonshares730,938,157
HangzhouHuadongMedicineGroupCo.,Ltd.288,000,000RMBcommonshares288,000,000
HongKongSecuritiesClearingCompanyLimited38,923,330RMBcommonshares38,923,330
NewChinaLifeInsuranceCo.,Ltd.-Dividend-IndividualDividend-018L-FH002Shenzhen35,903,842RMBcommonshares35,903,842
NewChinaLifeInsuranceCo.,Ltd.-Traditional-GeneralInsuranceProducts-018L-CT001Shenzhen23,204,014RMBcommonshares23,204,014
IndustrialandCommercialBankofChinaLimited-ZhongOuAMCMedicalandHealthHybridSecuritiesInvestmentFund21,182,329RMBcommonshares21,182,329
ChinaSecuritiesFinanceCorporationLimited19,095,344RMBcommonshares19,095,344
NationalSocialSecurityFund-Portfolio11217,589,744RMBcommonshares17,589,744
BankofShanghaiCo.,Ltd.-YinhuaCSIInnovativePharmaceuticalIndustryTradedOpen-endedIndexSecuritiesInvestmentFund13,013,898RMBcommonshares13,013,898
ChinaConstructionBankCorporation-EFundCSI300MedicalandHealthTradingOpenIndexSecuritiesInvestmentFund12,343,870RMBcommonshares12,343,870
Explanationonassociatedrelationshipsorconcertedactionsamongtheabove-mentionedshareholdersTheCompanyisunawareofwhethertheabove-mentionedshareholdersarerelatedpartiesorwhethertheyareconcertpartieswithoneanother.
Descriptionoftheparticipationinsecuritiesmargintradingbusinessoftop10shareholders(ifany)Asoftheendofthecurrentreportingperiod,noneofthetop10commonshareholdersoftheCompanyheldsharesoftheCompanythroughsecuritiesmargintradingaccounts.

Participationinthelendingofsharesthroughrefinancingbusinessofshareholdersholdingmorethan5%ofshares,top10shareholdersandtop10shareholdersholdingtradableshareswithouttradingrestriction

□Applicable?NotapplicableChangeintop10shareholdersandtop10shareholdersholdingtradableshareswithouttradingrestrictionduetolending/returningofsharesthroughrefinancingascomparedtothepreviousperiod

□Applicable?Notapplicable

(II)Totalnumberofpreferredshareholdersandshareholdinglistoftop10preferredshareholdersoftheCompany

□Applicable?Notapplicable

Ⅲ.OtherImportantMatters?Applicable□Notapplicable(I)OverviewoftheCompany'soveralloperationsduringthereportingperiodIn2026,externalcompetitionisexpectedtocontinueintensifying,andthepolicyenvironmenthasbecomeincreasinglycomplexandvolatile.Corporatedevelopmentfacesmountingpressures.Competitiondrivenbymarketsharewillenteranewstage.Duringthereportingperiod,inthefaceofthesechallenges,theCompanyhasremainedfirmlyalignedwithitsoverallstrategicroadmapandannualoperationalobjectives.Guidedbythebusinessprioritiesof"exploringnewmarkets,focusingonnewproducts,strengtheningorganizationalcapabilities,andbuildingnewcompetencies",theCompanyhasupheldthemanagementphilosophyof"problem-solvingandvaluecreation",andintegratedtheprinciplesof"innovation-drivendevelopment,resourceintegration,andenterprise-widecollaboration"throughoutalloperationalprocesses;stayingcommittedtoitsinnovation,theCompanyhassystematicallyadvancedcomprehensiveupgradesacrossitsproductportfolio,managementsystems,andtalentdevelopment.ItconcentratedresourcesontacklingkeyR&Dandclinicalstudyprograms,deepenedcollaborationacrosssectorssuchaspharmaceuticals,medicalaesthetics,andcommercialoperations,continuouslyactivatedgrowthdriversforinnovativebusiness,andrealizedsteadyimprovementsinoperationalqualityandmanagementefficiency,ensuringtheorderlyexecutionofvarioustasks.

Duringthereportingperiod,theCompanyachievedoperatingrevenueofRMB11.183billion,representingaYoYincreaseof4.17%andaquarter-on-quarterincreaseof2.15%comparedwithQ42025.NetprofitattributabletoshareholdersofthelistedcompanyreachedRMB1.002billion,up9.56%year-on-year.Netprofitattributabletoshareholdersexcludingnon-recurringprofitandlossitemswasRMB990million,markingaYoYincreaseof10.30%andreachingahistoricalhighforthesameperiod.Duringthereportingperiod,ZhongmeiHuadong,theCompany'scoresubsidiaryinthefieldofpharmaceuticalindustry,maintainedsteadygrowthinoveralloperations.Itachievedoperatingrevenue(includingCSObusiness)ofRMB4.048billion,representingan11.82%YoYincrease.TheconsolidatednetprofitattributabletotheparentcompanyreachedRMB931million,up

10.44%year-on-year.Bothoperatingrevenueandnetprofitattributabletotheparentcompanyrecordedthegrowthexceeding10%.

Duringthereportingperiod,therevenuecontributionofinnovativeproductscontinuedtoincrease.SalesandagencyservicerevenuegeneratedfrominnovativeproductsreachedRMB810

million,representingayear-on-yeargrowthof61.8%andaccountingfor20.05%oftheoperatingrevenueofthepharmaceuticalindustrysegment(includingtheCSObusiness).TheoverallbusinessoftheCompanyhasenteredastronggrowthtrajectory,furtherdemonstratingtheeffectivenessoftheCompany’sR&Dachievementtransformationandtheprofessionalismofitscommercializationoperations.Bytheendofthefirstquarterof2026,medicalinstitutionsthatwerecertifiedandregisteredtoadministertheCAR-TtherapyZevorcabtageneAutoleucelInjection(zevor-cel)hadexpandedtomorethan20provincesandmunicipalitiesacrossthecountry.Zevor-celhasalsobeenincludedintheCommercialHealthInsuranceInnovativeDrugList.AsofthedateofthisReport,morethan100commercialandHuiminbao(acity-specificsupplementalmedicalinsuranceprogram)programshaveincorporatedzevor-celintotheirreimbursementcoverage.Sinceitslaunch,Sailexin

?

,thebiosimilarofUstekinumabInjection,hasdemonstratedoutstandingmarketperformance.Todate,ithasbeenprescribedinover2,000hospitals,anditssalesrevenueinthefirstquarterof2026increasedbynearly200%yearonyear.Inthediabetesfield,Huiyoujing

?

,i.e.,GanagliflozinProlineTablets,whichistheClass1newdrug,hasnowbeenadoptedbyover1,900tieredhospitals.Itssalesrevenueinthefirstquarterof2026increasedbyover800%yearonyear(notingthatthefirstquarterof2025wasitsfirstsalesperiodafterinclusioninthenationalreimbursementdruglist).Bytheendofthefirstquarter,MirvetuximabSoravtansineInjection(tradename:ELAHERE

?)hadbeenlistedondrugprocurementplatformsin29provinces,prescribedinover200hospitals,andmadeavailableinmorethan400medicalinstitutionsandover200DTPpharmacies.Currently,Elahere

?hasalsobeensuccessfullyincorporatedinmultipleHuiminbao(acity-specificsupplementalmedicalinsuranceprogram)programsandcommercialinsuranceprograms,suchasBeijingInclusiveMedicalInsuranceProgram,JiangxiGanhuibao(inclusivecommercialhealthinsuranceprogram),LeshanHuijiabao(city-customizedinsuranceprogram),andShaanxiUniversalHealthInsurance.From2025totheendofthereportingperiod,cumulativesalesofElahere

?

exceededRMB100million.ThenovelPARPinhibitor,SenaparibCapsules(tradename:

Paishuning

?

),exclusivelypromotedbytheCompany,hasdeliveredoutstandingmarketperformance.Currently,itisavailableinover300DTPpharmaciesandmorethan900medicalinstitutions,supportedbyamulti-tierdistributionnetwork;atthesametime,theCompanyactivelypromotedtheinclusionofitsproductinreimbursementcoverageofinsuranceprograms.TheproducthasbeenincorporatedintomultipleregionalHuiminbaoprograms(e.g.,WestLakeYilianbao,Huhuibao,Chonghuibao,JiaxingHuiminbao,andCPIC-Huxiangbao),aswellasothercommercialinsuranceprograms,effectivelyreducingthefinancialburdenofpatients.

MediBeacon

?

TGFR,theworld’sfirstbedsiderenalfunctionassessmentdeviceapplicableto

patientswithnormalorimpairedrenalfunction,hasofficiallycommencedcommercialsalesintheChinesemarket.Todate,consumablesofMediBeacon

?TGFRhavebeenlistedin25provinces,whileRelmapirazinInjectionhasbeenlistedin21provinces.

Duringthereportingperiod,thepharmaceuticaldistributionsegmentoftheCompanysustainedstableoperations,yieldinganaggregateoperatingrevenueofRMB7.181billion,markingayear-on-year(YoY)uptickof3.57%,andanetprofitofRMB119million,representinga3.16%YoYincrease.Overall,itdemonstratedarobustdevelopmentaltrajectory.Affectedbymultiplefactorssuchasthecyclicalfluctuationsintheglobaleconomy,intensifiedindustrycompetition,andslower-than-expectedrecoveryindomesticaestheticmedicineconsumption,theCompany'saestheticmedicinesegmentcontinuedtoconfrontgrowthheadwinds.Throughoutthereportingperiod,itachievedatotaloperatingrevenueofRMB361million(excludinginternaloffsets),reflectingaYoYdeclineof30.38%.

OnMarch25,2026,theCompany'sexclusivelydistributedproduct,RecombinantBotulinumToxinTypeAforInjection(R&Dcode:YY001;tradename:Retoxin

?),receivedmarketingapprovalfromtheNationalMedicalProductsAdministration(NMPA).Thisproductisindicatedforthetemporaryameliorationofmoderate-to-severeglabellarlinesinadultsaged65andunder,resultingfromtheactivityofthecorrugatorsuperciliiand/orprocerusmuscles.Thisproductispoisedtoinitiateformalcommercialsalesinthenearfuture.

Duringthereportingperiod,theCompany'sindustrialmicrobiologysegmentcontinuedtoexperiencerelativelyrapidrevenuegrowth,withaYoYincreaseof21.82%.Giventheproactiveexpansionintooverseasmarketsandaconsistentuptickinorders,thissegmentisanticipatedtoupholditsfavorabledevelopmentalmomentum.

(II)ImportantR&DprogressoftheCompanyduringthereportingperiod

1.Majorprogressininnovation-drivenR&Dduringthereportingperiod

Oncology

HDM2005,anantibody-drugconjugate(ADC)targetingROR1,hasmaintaineditsleadingpositionwithintheglobalfirstechelonofclinicaldevelopmentforROR1ADCs.Presently,threeclinicalstudiesarebeingconductedinChina:aPhaseIclinicalstudyevaluatingmonotherapyforadvancedhematologicmalignancies,includingmantlecelllymphoma(MCL),diffuselargeB-celllymphoma(DLBCL),andclassicalHodgkinlymphoma(cHL).ThisstudyhascompletedPhaseIamonotherapydoseescalationandiscurrentlyperformingdoseexpansionstudiesforMCLandcHL.AnotherPhaseIstudy,assessingmonotherapyforadvancedsolidtumors,hasenrolled17patientsandisconductingdoseexpansionatadosageof2.5mg/kg.Additionally,aPhaseIb&IIclinical

studyinvestigatingcombinationtherapyforDLBCLpatientsiscurrentlyundergoingcombinationtherapydoseescalation.Inaddition,theCompanyhassubmittedcommunicationandmeetingrequeststotheCDE,respectively,forcombinationtherapyinMCLandcHL.TheclinicalstudyfordoseescalationofmonotherapyinvolvingHDM2020,anADCtargetingFGFR2b,hasadvancedtothefourthdosecohort.Furthermore,aPhaseIastudyforlungsquamouscellcarcinomahasofficiallycommenced,withsubjectscreeningcurrentlyinprogress.InFebruary2026,HDM2020wasgrantedorphandrugdesignation(ODD)bytheU.S.FDAforgastriccancer(includinggastroesophagealjunctioncancer).

HDM2012,anADCtargetingMUC17,hasreachedthefourthdosecohortinitsPhaseIclinicalstudyaimedattreatingadvancedsolidtumors.HDM2017,targetingCDH17,hasprogressedtothefourthdosecohortinitsPhaseIamonotherapytrialinChina,withconcurrentdoseexpansionatadosageof3.2mg/kg.ThefirstAustraliansitewasactivatedinFebruary2026,andsubjectscreeningisongoing.Inaddition,inMarch2026,HDM2017receivedODDfromtheU.S.FDAforthreeindications:biliarytractcancer,gastriccancer,andpancreaticcancer.HDM2024,anEGFR/HER3-targetingbispecificADC,receivedINDapprovalsintheUnitedStatesandChinainMarch2026forthetreatmentofadvancedsolidtumors.ThefirstsubjectadministrationinaPhaseIclinicalstudyinChinawascompletedinApril2026.

HDP-101(HDM2027),aBCMA-targetingamanitinADC,enrolleditsfirstpatientinChinainMarch2026forthetreatmentofplasma-celldisorders,includingmultiplemyeloma.

Thesmall-moleculeantineoplasticagentHPK-1PROTAC(hematopoieticprogenitorkinase1proteolysis-targetingchimera),HDM2006tablets,iscurrentlyundergoingaPhaseIclinicalstudyinChinaforthetreatmentofadvancedsolidtumors,withenrollmentforthethirddosecohortunderway.

DR30206forinjection,aproprietaryPD-L1/VEGF/TGF-βtri-specificantibodyfusionprotein,developedbyDoerBiologics,acontrolledsubsidiaryoftheCompany,isnearingthecompletionofdoseexpansionstudiesinitsPhaseIbtrialforthefirst-linetreatmentofnon-smallcelllungcancer,demonstratingpromisingoverallefficacy.Theprogramisadvancingitscombinationtherapystudy.PhaseIb/IIaclinicalstudiesevaluatingcombinationtherapywithstandardchemotherapyforadvancedormetastaticgastrointestinaltumors,aswellasPhaseIbmonotherapyexpansionstudiesforheadandnecksquamouscellcarcinomacohorts,arecurrentlyunderway.InJanuary2026,theDR30206wasadministeredtothefirstsubjectinthemonotherapyexpansioncohortforplatinum-resistantovariancancerduringitsPhaseIbtrial.InMarch2026,DR30206receivedINDapprovalinChinaforitscombinationwithstandardchemotherapyinpatientswithlocallyadvancedor

metastaticnon-smallcelllungcancer.

EndocrinologyHDM1002(conveglipron),theoralsmall-moleculeGLP-1receptoragonist,hascompletedenrollmentofallsubjectsforitsPhaseIIIclinicalstudyinChinafortheweightmanagementindication.Thestudyiscurrentlyinthestageoftreatmentfollow-upanddatacollection.TheNDAapplicationisexpectedtobesubmittedinQ42026.BothPhaseIIIclinicalstudiesforthetype2diabetesmellitusindicationofthisproducthavecompletedfullenrollment.Pre-NDAcommunicationapplicationisexpectedtobesubmittedinQ42026.HDM1005(poterepatide)Injection,aGLP-1R/GIPRlong-actingpolypeptidedual-targetagonist,enrolledallsubjectsinthePhaseIIIclinicalstudyfortheweightmanagementindication.Top-lineresultsforthePhaseIIclinicalstudyfordiabeteswereobtainedinFebruary2026.ThefirstsubjectshavebeenenrolledinbothPhaseIIIstudiesfordiabetes.TwoPhaseIIIstudiesfortheobstructivesleepapneahypopneasyndrome(OSAS)indicationarecurrentlyinpreparation.

DR10624,afirst-in-classtherapeuticcandidatetargetingFGF21R/GCGR/GLP-1RanddevelopedbyDoerBiologics,acontrolledsubsidiaryoftheCompany,iscurrentlyprogressingwithpreparationsforitsPhaseIIIclinicalstudyaimedattreatingseverehypertriglyceridemia.InJanuary2026,DR10624wasincludedintheBreakthroughTherapyDesignationbytheCDEforseverehypertriglyceridemia.ThePhaseIIclinicalstudytargetingpatientswithmetabolicdysfunction-associatedsteatoticliverdiseasewithhighriskofliverfibrosisiscurrentlybeingconductedconcurrently.Top-lineresultsareexpectedtobeobtainedinQ32026.

HDM1014injection,whichistheGalNAc-siRNAweight-lossdrugself-developedbytheCompany,isundergoingINDdevelopmentwork.ItisexpectedtosubmitINDapplicationinChinainQ42026.

TheINDapplicationforHDM1010tablets(afixed-doseoralcombinationformulationofHDM1002)intendedforthetreatmentoftype2diabetesmellitushasreceivedapprovalfromtheU.S.FDA.Clinicalstudypreparationsarecurrentlyinfullswing.

TheNDAforthediabetesindicationofSemaglutideInjectionwassubmittedandacceptedinMarch2025andsuccessfullypassedclinicalinspection;theNDAfortheweightmanagementindicationwasacceptedinApril2026.

TheNDAforInsulinDegludecInjectionwassubmittedandacceptedinFebruary2025;theon-siteinspectionhasbeencompleted,andtheapplicationiscurrentlyundertechnicalreview.

Thetop-lineresultsfromthePhaseIIIclinicalstudyofInsulinDegludecandInsulinAspartInjectionhavebeenobtained.ItisexpectedtosubmitNDAintheQ2of2026.

Autoimmunity

TheMarketingAuthorizationApplication(MAA)andsupplementalapplicationforHDM3001(QX001S),austekinumabbiosimilardevelopedincollaborationwithQyunsTherapeuticsforthetreatmentofCrohn'sdisease,areexpectedtoreceiveapprovalintheQ2of2026.ThePhaseIIIclinicalstudiesfortheinnovativedrugOturkibart(R&Dcode:

HDM3016/QX005N),whichwasdevelopedbytheCompanyincollaborationwithQyunsTherapeuticsforthetreatmentofprurigonodularis(PN)andatopicdermatitis(AD)havereachedtheirprimaryendpoints.TheNDAsforthePNandADindicationsareexpectedtobesubmittedinthefirstandsecondhalvesof2026,respectively.

TheChineseNDAapplicationsforHDM3014(RoflumilastCream),developedincollaborationwithArcutisintheUnitedStatesfortwoindications—plaquepsoriasisinpatientsaged6andabove,andatopicdermatitisinpatientsaged6andabove—havesuccessfullypassedtheclinicalon-siteinspectionconductedbytheNationalMedicalProductsAdministration.Inaddition,theChineseNDAapplicationforRoflumilastCreamforatopicdermatitisindicationinpatientsaged2to5wasacceptedinFebruary2026.

ThePhaseI/IIclinicalstudyevaluatingRuxolitinibGel(HDM3010),amodifiednewdrugdevelopedbytheCompany,forthetreatmentofprurigonodularishasyieldedtop-lineresults.TheCompanyhasreceivedfeedbackfromtheCenterforDrugEvaluation(CDE)andarecurrentlymakingpreparationsforsubsequentstudiesbasedonthisfeedback.Inaddition,aPhaseIIIclinicalstudyinvitiligoiscurrentlyongoing.

ThePhaseIIIclinicalstudyofMC2-01Cream,developedthroughacollaborationbetweentheCompanyandMC2Therapeuticsforthetreatmentofplaquepsoriasis,hasenrolledmorethan120subjectsinChinatodate.

HDM4002Injection,thefirst-in-classbispecificantibodycandidateindependentlydevelopedbytheCompany,iscurrentlyundergoingIND-enablingdevelopment.ItisanticipatedthatINDapplicationswillbesubmittedinbothChinaandtheUnitedStatesin2026.

Othersegments

TheNDAforRanibizumabInjectionwassubmittedandacceptedinMay2025.Subsequently,theon-siteinspectionhasbeencompletedfortheproduction.RanibizumabInjectionhassuccessfullypassedtheclinicalon-siteinspectionconductedbytheNationalMedicalProductsAdministration.

2.Registrationmilestonesforkeyinnovativeproductssince2026

TypeItemCategoryChinaRegistrationClassMilestoneEvent
NDASAILEXIN?BiosimilarClass3.3Supplementalapplicationfornewstrengths
acceptance(UstekinumabInjection)therapeuticbiologicalproductofCrohn'sdiseasewasacceptedinJanuary2026
0.05%RoflumilastCreamInnovativedrugClass5.1chemicaldrugNDAwasacceptedinFebruary2026
SemaglutideInjectionBiosimilarClass3.3therapeuticbiologicalproductNDAforweightmanagementindicationwasacceptedinApril2026
BudesonideandFomoterolPowderforInhalation(IV),CapsuletypeModifiednewdrugClass2.2chemicaldrugNDAacceptedinApril2026
INDapprovedDR10624InnovativedrugClass1therapeuticbiologicalproductTheINDformetabolicdysfunction-associatedsteatoticliverdiseasewasapprovedintheU.S.inJanuary2026
HDM2005InnovativedrugClass1therapeuticbiologicalproductTheINDforthecombinationtherapywithRituximabandLenalidomideforthetreatmentofrelapsed/refractorymantlecelllymphomawasapprovedinChinainJanuary2026
DR10624InnovativedrugClass1therapeuticbiologicalproductINDforhypertriglyceridemiaapprovedinChinainFebruary2026
DR30206InnovativedrugClass1therapeuticbiologicalproductTheINDforcombinationwithstandardchemotherapyinlocallyadvancedormetastaticnon-smallcelllungcancerpatientswasapprovedinChinainFebruary2026
HDM2024InnovativedrugClass1therapeuticbiologicalproductTheINDforadvancedmalignantsolidtumorswasapprovedinChinainMarch2026
HDM2024InnovativedrugClass1therapeuticbiologicalproductTheINDforadvancedmalignantsolidtumorswasapprovedintheU.S.inMarch2026
OrphandrugdesignationHDM2020InnovativedrugClass1therapeuticbiologicalproductOrphandrugdesignationwasgrantedintheU.S.inFebruary2026forindicationsofgastriccancerandgastroesophagealjunctioncancer
HDM2017InnovativedrugClass1therapeuticbiologicalproductOrphandrugdesignationwasgrantedintheU.S.inMarch2026forbiliarytractcancerindication
HDM2017InnovativedrugClass1therapeuticbiologicalproductOrphandrugdesignationwasgrantedintheU.S.inMarch2026forgastriccancerindication
HDM2017InnovativedrugClass1therapeuticbiologicalproductOrphandrugdesignationwasgrantedintheU.S.inMarch2026forpancreaticcancerindication
BreakthroughtherapyDR10624InnovativedrugClass1therapeuticbiologicalproductChinesebreakthroughtherapydesignationwasobtainedinJanuary2026forseverehypertriglyceridemia

Note:BudesonideandFomoterolPowderforInhalation(IV)(capsuletype)istheproductexclusivelycommercializedbytheCompanyintheChinesemainland.

3.TheCompany'spharmaceuticalinnovationachievementspresentedatinternationalacademicconferencessince2026

No.DateofreleaseItemConference/journalnamePresentationformatTitle
1March2026HDM3014AmericanAcademyofDermatologyOralEfficacyandSafetyofRoflumilastCream0.3%inChineseAdultand
(AAD)PediatricPatientswithPlaquePsoriasis:ResultsFromaPhase3Trial
2March2026HDM3014AmericanAcademyofDermatology(AAD)PosterpresentationRoflumilastCream0.15%forMild-to-ModerateAtopicDermatitis:AMulticenter,vehicle-ControlledPhase3BridgingStudyinChina
3March2026HD-NP-102SocietyofCriticalCareMedicine(SCCM)OralClinicalValidationofaTransdermalGFRMeasurementSysteminChineseIndividuals
4March2026HD-NP-102SocietyofCriticalCareMedicine(SCCM)OralBioequivalenceandEfficacyStudyofMB-102WithTransdermalGFRMeasurementinChineseSubjects
5April2026HDM2021AmericanAssociationforCancerResearch(AACR)PosterpresentationHDM2021,apotentandselectiveCBL-Binhibitorexhibitsrobustimmunomodulatoryefficacyforanti-tumortherapy
6April2026HDM2024AmericanAssociationforCancerResearch(AACR)PosterpresentationAnovelEGFRandHER3bispecificantibody-drugconjugateexhibitssuperiorantitumoractivityandfavorabletoxicologicalprofile
7April2026DR319AmericanAssociationforCancerResearch(AACR)PosterpresentationDR319-DP:ANectin-4/Trop-2bispecificADCwithanavidity-drivenVHHdesignanddual-MOApayloads

(III)Activitiessuchasresearch,communication,andinterviewsconductedduringthereportingperiod

ReceptiondateReceptionaddressReceptionmethodTypeofvisitorVisitorsMaincontentofdiscussionandinformationprovidedIndexofbasicinformationoftheresearch
January21and22,2026ConferenceroomoftheCompanyFieldvisitsInstitutionsandindividualsGuotaiHaitongSecurities,TFSecurities,ZheshangSecurities,etc.InvestorcommunicationFordetails,pleaserefertotheRecordSheetofInvestorRelationsActivitiesonJanuary21and22,2026publishedbytheCompanyathttps://irm.cninfo.com.cn/andatwww.cninfo.com.cn.

IV.QuarterlyFinancialStatements(I)Financialstatements

1.Consolidatedbalancesheet

Preparedby:HuadongMedicineCo.,Ltd.

March31,2026

Unit:RMB

ItemClosingbalanceOpeningbalance
Currentassets:
Monetaryfunds3,734,865,777.194,978,052,188.84
Depositreservationforbalance
Lendingstobanksandotherfinancialinstitutions
Tradingfinancialassets
Derivativefinancialassets
Notesreceivable6,213,394.05
Accountsreceivable11,076,591,135.348,985,587,945.31
Receivablesfinancing332,387,014.92460,578,206.16
Prepayments508,155,787.14445,803,941.09
Premiumreceivable
Reinsuranceaccountsreceivable
Reinsurancecontractreservereceivable
Otherreceivables609,897,223.80517,535,129.39
Incl.:Interestreceivable
Dividendsreceivable223,608.84223,608.84
Financialassetspurchasedforresale
Inventory5,327,579,147.015,535,765,919.86
Incl.:Dataresources
Contractassets
Assetsheldforsale
Non-currentassetsduewithinoneyear75,464,880.5475,464,880.54
Othercurrentassets139,274,907.01222,343,329.23
Totalcurrentassets21,804,215,872.9521,227,344,934.47
Non-currentassets:
Loansandadvancesissued
Debtinvestments
Otherdebtinvestments
Long-termreceivables
Long-termequityinvestment1,629,415,091.831,509,122,017.22
Investmentinotherequityinstruments682,132,315.02681,006,253.76
Othernon-currentfinancialassets
Investmentproperty10,694,501.0510,946,776.47
Fixedassets4,389,958,201.124,470,264,264.88
Constructioninprogress931,509,517.77832,431,516.18
Productivebiologicalassets
Oilandgasassets
Right-of-useassets158,409,996.23170,395,474.59
Intangibleassets3,922,211,412.973,849,691,624.59
Incl.:Dataresources
Developmentexpenditure1,943,582,627.601,757,196,902.53
Incl.:Dataresources
Goodwill2,848,210,102.922,860,135,566.37
Long-termdeferredexpenses18,776,159.1419,541,767.43
Deferredincometaxassets385,084,524.44385,084,524.45
Othernon-currentassets1,183,842,241.901,264,874,697.98
Totalnon-currentassets18,103,826,691.9917,810,691,386.45
Totalassets39,908,042,564.9439,038,036,320.92
Currentliabilities:
Short-termborrowings1,714,508,902.521,621,903,523.77
Borrowingsfromthecentralbank
Borrowingsfromotherbanksandotherfinancialinstitutions
Tradingfinancialliabilities
Derivativefinancialliabilities
Notespayable3,017,614,936.172,910,051,094.08
Accountspayable4,591,952,103.815,059,850,765.02
Advancereceipts502,191.65797,358.84
Contractliabilities232,364,085.08188,554,462.61
Expenseforfinancialassetssoldforrepurchase
Depositstakenandinterbankdeposits
Receivingsfromvicariouslytradedsecurities
Receivingsfromvicariouslysoldsecurities
Employeecompensationpayable237,138,507.68411,598,841.94
Taxesandduespayable553,756,331.70563,317,023.92
Otherpayables2,567,376,516.562,215,275,211.55
Incl.:Interestspayable
Dividendspayable101,810,219.60102,560,219.60
Handlingchargesandcommissionspayable
Reinsuranceaccountspayable
Liabilitiesheldforsale
Non-currentliabilitiesduewithinoneyear82,978,800.49108,871,732.55
Othercurrentliabilities34,942,891.8010,443,641.94
Totalcurrentliabilities13,033,135,267.4613,090,663,656.22
Non-currentliabilities:
Provisionforinsurancecontracts
Long-termborrowings251,619,962.82252,034,854.55
Bondspayable
Incl.:Preferredshare
Perpetualbonds
Leaseliabilities111,057,382.9288,813,504.20
Long-termpayables
Long-termemployeecompensationpayable
Estimatedliabilities19,922,759.6120,617,015.41
Deferredrevenue187,359,036.43190,942,291.61
Deferredincometaxliabilities217,236,393.17223,959,318.75
Othernon-currentliabilities
Totalnon-currentliabilities787,195,534.95776,366,984.52
Totalliabilities13,820,330,802.4113,867,030,640.74
Owners'equity:
Sharecapital1,753,736,848.001,753,736,848.00
Otherequityinstruments
Incl.:Preferredshare
Perpetualbonds
Capitalreserve2,416,510,921.202,416,358,618.64
Less:Treasuryshare
Othercomprehensiveincome-74,836,933.545,770,687.07
Specialreserves
Surplusreserves1,616,443,486.391,616,443,486.39
Generalriskreserves
Retainedearnings20,021,219,710.0519,019,030,352.89
Totalowners'equityattributabletotheparentcompany25,733,074,032.1024,811,339,992.99
Minorityinterests354,637,730.43359,665,687.19
Totalowners'equity26,087,711,762.5325,171,005,680.18
Totalliabilitiesandowners'equity39,908,042,564.9439,038,036,320.92

Legalrepresentative:LvLiangOfficerinchargeofaccounting:LvLiangHeadofAccountingDepartment:QiuRenbo

2.Consolidatedincomestatement

Unit:RMB

ItemAmountincurredinthecurrentperiodAmountincurredinthepreviousperiod
I.Totaloperatingrevenue11,183,450,824.2710,735,787,899.82
Incl.:Operatingrevenue11,183,450,824.2710,735,787,899.82
Interestincome
Premiumsearned
Handlingchargesandcommissionsrevenue
II.Totaloperatingcosts9,992,872,896.349,620,007,130.43
Incl.:Operatingcosts7,387,443,870.047,206,598,136.26
Interestexpenditure
Handlingchargesandcommissionsexpenditure
Surrendervalue
Netpaymentsforinsuranceclaims
Netprovisionforinsuranceliabilities
Expenseforinsurancepolicydividends
Reinsuranceexpenses
Taxesandsurcharges67,774,008.0957,265,200.91
Sellingexpenses1,820,619,488.781,470,753,504.47
Managementexpenses371,395,501.48355,395,350.66
R&Dexpenses350,365,327.14515,376,918.47
Financialexpenses-4,725,299.1914,618,019.66
Incl.:Interestexpense19,176,576.8425,924,507.30
Interestincome20,155,981.8927,812,843.06
Plus:Otherincomes31,230,304.0273,641,636.88
Investmentincome(lossexpressedwith"-")-22,310,345.97-42,624,149.61
Incl.:Investmentincomeinassociatesandjointventures-7,510,017.34-28,249,462.69
Incomefromderecognitionoffinancialassetsmeasuredonthebasisofamortizedcosts
Exchangeearnings(lossexpressedwith"-")
Netincomeofexposurehedge(lossexpressedwith"-")
Incomefromchangesinfairvalue(lossexpressedwith"-")
Creditimpairmentloss(loss
expressedwith"-")
Assetimpairmentloss(lossexpressedwith"-")
Proceedsfromdisposalofassets(lossexpressedwith"-")534,949.84-14,540,990.32
III.Operatingprofit(lossexpressedwith"-")1,200,032,835.821,132,257,266.34
Plus:Non-operatingrevenue1,256,954.75769,095.39
Less:Non-operatingexpenses9,095,444.6428,075,417.91
IV.Totalprofit(totallossexpressedwith"-")1,192,194,345.931,104,950,943.82
Less:Incometaxexpense195,032,945.55190,966,760.40
V.Netprofit(netlossexpressedwith"-")997,161,400.38913,984,183.42
(I)Classificationbycontinuityofoperation
1.Netprofitsfromcontinuingoperations(netlossexpressedwith"-")997,161,400.38913,984,183.42
2.Netprofitfromdiscontinuedoperations(netlossexpressedwith"-")
(II)Classificationbyownership
1.Netprofitattributabletotheownersoftheparentcompany1,002,189,357.16914,708,484.70
2.Minorityinterestincome-5,027,956.78-724,301.28
VI.Othercomprehensiveincome(netoftax)-80,607,620.6182,044,972.47
Othercomprehensiveincomeattributabletotheowneroftheparentcompany(netoftax)-80,607,620.6182,044,972.47
(I)Othercomprehensiveincomethatcannotbereclassifiedintotheprofitsandlosses
1.Changefromre-measurementofdefinedbenefitplan
2.Othercomprehensiveincomethatcannotbeincludedintheprofitsandlossesundertheequitymethod
3.Changesinfairvalueofinvestmentinotherequityinstruments
4.Changesinfairvaluebytheenterprise'screditrisks
5.Others
(II)Othercomprehensiveincomethatwillbereclassifiedintotheprofitsandlosses-80,607,620.6182,044,972.47
1.Othercomprehensiveincomethatcanbetransferredtotheprofitandlossundertheequitymethod
2.Changesinfairvalueofinvestmentsinotherdebtinvestments
3.Financialassetsreclassifiedintoothercomprehensiveincome
4.Provisionforcreditimpairmentofotherdebtinvestments
5.Cashflowhedgingreserves
6.Converteddifferenceinforeigncurrencyfinancialstatements-80,607,620.6182,044,972.47
7.Others
Othercomprehensiveincomeattributabletominorityshareholders(netoftax)
VII.Totalcomprehensiveincome916,553,779.77996,029,155.89
Totalcomprehensiveincomeattributabletotheowneroftheparentcompany921,581,736.55996,753,457.17
Totalcomprehensiveincomeattributabletominorityshareholders-5,027,956.78-724,301.28
VIII.Earningspershare:
(I)Basicearningspershare0.57150.5224
(II)Dilutedearningspershare0.57150.5213

Ifthereisabusinesscombinationundercommoncontrolinthisperiod,thenetprofitofthecombinedpartybeforethecombinationisRMB0.00,andthenetprofitofthecombinedpartyinthepreviousperiodisRMB0.00.Legalrepresentative:LvLiangOfficerinchargeofaccounting:LvLiangHeadofAccountingDepartment:QiuRenbo

3.Consolidatedcashflowstatement

Unit:RMB

ItemAmountincurredinthecurrentperiodAmountincurredinthepreviousperiod
I.Cashflowsfromoperatingactivities:
Cashreceivedfromsellinggoodsandprovidingservices10,376,323,259.389,882,552,619.72
Netincreaseindepositsfromcustomersaswellasbanksandotherfinancialinstitutions
Netincreaseinborrowingsfromthecentralbank
Netincreaseinborrowingsfromotherfinancialinstitutions
Cashreceivedfromtheoriginalinsurancecontractpremium
Netcashreceivedfromreinsurancebusiness
Netincreaseindepositsandinvestmentsfrompolicyholders
Cashreceivedfrominterests,handlingchargesandcommissions
Netincreaseinborrowingsfrombanksandotherfinancialinstitutions
Netincreaseinfundsfromrepurchasebusiness
Netcashreceivedfromsecuritiestradingagency
Refundoftaxesandfeesreceived2,570,131.002,055,460.55
Receiptofothercashrelatingtooperatingactivities124,934,981.83230,013,343.26
Subtotalofcashinflowsfromoperatingactivities10,503,828,372.2110,114,621,423.53
Cashpaidforpurchaseofgoodsandreceiptoflaborservices7,960,726,465.367,695,820,108.31
Netincreaseincustomerloansandadvancepayments
Netincreaseindepositswiththecentralbankandinterbank
Cashforpaymentoftheoriginalinsurancecontract
Netincreaseinlendingstobanksandotherfinancialinstitutions
Cashpaidforinterests,handlingchargesandcommissions
Cashforpaymentofdividendsonpolicies
Cashpaidtoandforemployees1,542,554,152.981,441,219,423.87
Varioustaxesandfeespaid709,327,509.54671,816,951.08
Paymentofothercashrelatingtooperatingactivities1,143,556,006.961,138,493,634.15
Subtotalofcashoutflowsfromoperatingactivities11,356,164,134.8410,947,350,117.41
Netcashflowfromoperatingactivities-852,335,762.63-832,728,693.88
II.Cashflowsfrominvestingactivities:
Cashreceivedfrominvestmentrecovery
Cashreceivedfromobtaininginvestmentincome43,350,000.00
Netcashrecoveredfromdisposaloffixedassets,intangibleassetsandotherlong-termassets74,063.519,751,907.00
Netcashreceivedfromdisposalofsubsidiariesandotherbusinessunits
Receiptofothercashrelatingtoinvestingactivities
Subtotalofcashinflowsfrominvestingactivities74,063.5153,101,907.00
Cashpaidforthepurchaseandconstructionoffixedassets,intangibleassetsandotherlong-termassets261,855,876.92637,322,382.41
Cashpaidforinvestment129,618,537.8561,618,925.00
Netincreaseinpledgedloans
Netcashpaidforacquisitionofsubsidiariesandotherbusinessentities
Paymentsofothercashrelatingtoinvestingactivities
Subtotalofcashoutflowsfrominvestingactivities391,474,414.77698,941,307.41
Netcashflowsfrominvestingactivities-391,400,351.26-645,839,400.41
III.Cashflowsfromfinancingactivities:
Cashreceivedbyabsorbinginvestment
Incl.:Cashreceivedbysubsidiariesfromminorityshareholders'investment
Cashreceivedfromobtainingborrowings1,131,688,831.321,289,998,848.00
Receiptofothercashrelatingtofinancingactivities800,000.00146,000,000.00
Subtotalofcashinflowsfromfinancingactivities1,132,488,831.321,435,998,848.00
Cashpaidfordebtrepayment1,047,678,831.321,279,708,605.45
Cashpaidtodistributedividends,profitsorpayinterest37,291,974.4517,579,298.66
Incl.:Dividendsandprofitspaidbysubsidiariestominorityshareholders
Paymentofothercashrelatingtofinancingactivities12,306,031.36225,549,581.73
Subtotalofcashoutflowsfromfinancingactivities1,097,276,837.131,522,837,485.84
Netcashflowfromfinancingactivities35,211,994.19-86,838,637.84
IV.Effectofexchangeratechangesoncashandcashequivalents-4,179,294.34-3,115,685.50
V.Netincreaseincashandcashequivalents-1,212,703,414.04-1,568,522,417.63
Plus:Openingbalanceofcashandcashequivalents4,735,921,663.904,990,151,186.68
VI.Closingbalanceofcashandcashequivalents3,523,218,249.863,421,628,769.05

(II)SituationofrelevantitemsoffinancialstatementsatthebeginningofthecurrentyearaftertheinitialimplementationofadjustmentoftheNewAccountingStandardsin2026

□Applicable?Notapplicable

(III)Auditreport

HastheFirstQuarterlyFinancialReportbeenaudited?

□Yes?NoTheCompany’sFirstQuarterlyFinancialReporthasnotbeenaudited.

BoardofDirectorsofHuadongMedicineCo.,Ltd.

April24,2026


附件：公告原文
查股网为非盈利网站 如有版权问题 请联系 qq:767871486 或 767871486@qq.com